Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First Of Its Kind Blood Test Accurately Predicts Preterm Birth Risk

By LabMedica International staff writers
Posted on 17 Jan 2025

Preterm birth is one of the leading causes of childhood mortality worldwide. More...

The World Health Organization reports that over 15 million babies are born prematurely each year, with more than a million of them not surviving. Approximately 70% of preterm births occur spontaneously, without a medical indication. Black mothers are also twice as likely to experience preterm birth compared to White mothers, although the reasons for this disparity remain unclear. Now, a groundbreaking blood test has been developed that may predict the risk of preterm birth early in pregnancy.

Researchers at The Ohio State University (Columbus, OH, USA) developed this new blood test after studying various risk factors for preterm birth, including stressors such as early life adversity and experiences of racial discrimination. They discovered that persistent stress, poor sleep, depression, and anxiety can subtly alter the functioning of the immune system over time. These changes in immune function can be detected with a simple blood test, requiring less than a teaspoon of blood. Initial tests of the blood test show promising potential, with the ability to predict the risk of preterm birth with accuracy as high as 97.5%.

The researchers suggest that the test could be incorporated into the "prenatal battery," a set of screenings designed to help clinicians identify factors that may increase a patient's risk of preterm birth, allowing for early interventions before any symptoms appear. The team is now working to conduct a larger and more comprehensive study to ensure the test's accuracy in diverse patient populations. They are also exploring treatments that could "reset" the immune system’s responses to normal levels to further reduce the risk of preterm birth.

“We’re essentially trying to create this ‘crystal ball’ of future events. We are truly producing a future likely scenario early in pregnancy. And so, if the body’s not responding in the right way, we can see that,” said Shannon Gillespie, PhD, RN, FAAN, assistant professor at Ohio State’s College of Nursing. “It should feel as simple as a test for anemia. So things that can be available for everyone that’s interested.”


Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.